All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dato-DXd Approved in China for Previously Treated HR+, HER2– Negative Metastatic Breast Cancer

August 25th 2025

Datopotamab deruxtecan is approved in China for hormone receptor–positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy.

PDS0101 Plus Pembrolizumab Yields Durable Survival Benefit in HPV16+ HNSCC

August 25th 2025

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Divesiran Shows Promise as RNA-Based Approach in Polycythemia Vera

August 25th 2025

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

Fc-Enhanced Agents May Expand Anti–CTLA-4 Approaches in GI Cancers

August 25th 2025

To extend the benefits of CTLA-4 inhibitors to poorly immunogenic tumors such as HCC and CRC, investigators are developing Fc-enhanced CTLA-4 inhibitors.

Talquetamab/Teclistamab May Address Need for Improved Survival Outcomes in R/R Myeloma With Extramedullary Disease

August 25th 2025

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Observational Study Associates BRCA and Other HRR Gene Alterations With Poorer Outcomes in mHSPC

August 24th 2025

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

EMA Grants Orphan Drug Designation to Pegtarazimod for GVHD

August 23rd 2025

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Gene Therapy Efficacy and Safety Considerations May Refine BCG-Unresponsive NMIBC Management

August 22nd 2025

Alberto Martini, MD, discusses the safety of intravesical therapies in NMIBC, the efficacy of EG-70, and future trial needs in this population.

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Comorbidities

August 22nd 2025

Venetoclax plus obinutuzumab generated safe and efficacious real-world outcomes in first-line CLL with comorbidities.

City of Hope Study Shows Childhood Cancer Survivors Face New Health Problems Later in Life

August 22nd 2025

Researchers call for early screening as young patients live longer.

Darolutamide Wins Canadian Approval for mCSPC

August 22nd 2025

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Development Program for KB707 Will Prioritize Inhaled Formulation for NSCLC

August 22nd 2025

Krystal Biotech will prioritize the development of KB707 as an inhaled formulation for non–small cell lung cancer.

Health Canada Approves Glofitamab Plus Chemotherapy for R/R DLBCL

August 22nd 2025

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Genomic Tests for HR+/HER2– Early Breast Cancer Show Utility Beyond Predicting Prognosis

August 22nd 2025

Joyce O'Shaughnessy, MD, discusses the utility of genomic testing in HR+, HER2– early breast cancer.

BRF14 Data Demonstrate Long-Term Efficacy of Imatinib in Advanced GIST

August 22nd 2025

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies

August 22nd 2025

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Pivotal Study Data Support Further Research in BCG-Unresponsive, High-Risk NMIBC

August 21st 2025

Alberto Martini, MD discusses how systemic treatment approaches and key trials have refined care for patients with BCG-unresponsive NMIBC.

PARP Inhibitors and Radioligand Therapies Advance Prostate Cancer Care with Biomarker-Driven Strategies

August 21st 2025

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.